Intracellular single-chain antibodies (scFvs) have emerged as a powerful method to knock out expression of oncoproteins. We have demonstrated previously that scFvs directed against a variety of molecular targets induce specific toxicity in tumor cells. Recently, the utility of an anti-erbB-2 scFv has predicated its evaluation in a phase I gene therapy clinical trial. The utility of scFv as an intrabody is closely linked to its interaction with a target, limiting the contribution of the latter to the neoplastic phenotype. In this study, we sought to determine whether improvement in the affinity of the scFv for its cognate target could improve the efficiency of intrabody-mediated oncoprotein knockout. We compared in erbB-2-positive and -negative tumor cells the function of plasmids encoding a newly developed C6.5 anti-erbB-2 scFv, which has a 1000-fold higher affinity, with our original e23 anti-erbB-2 scFv. Intracellular scFv expression, target binding, and tumor cell cytotoxicity were found to be similar in all conditions tested, including dose-response studies with limiting dilutions of the scFv. On this basis, we have concluded that the antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.
C
ancer gene therapy of mutation compensation is based on rectification of the genetic lesions etiologic of neoplastic progression. 1 For the context of dominant oncogenes, methods have been developed to achieve abrogation of the dysregulated cellular pathways. [2] [3] [4] [5] [6] Such interventions have been endeavored at the transcriptional level of gene expression by using triplex, antisense, or ribozyme approaches. 4 -8 In addition, functional knockout at the level of protein expression has been achieved via dominant-negative mutation, as well as intrabody methods. 9 -16 This later approach is based on intracellular expression of single-chain antibodies (scFvs) to sequester oncoproteins during their biosynthesis, thus preventing their further maturation. 16 -20 On this basis, intrabody knockout of oncoproteins has found broad utility for a variety of molecular targets. In this regard, intrabody knockout of diverse classes of oncoproteins has been reported, including overexpressed growth factor receptors (erbB-2, epidermal growth factor-R), cell cycle proteins (cyclin D1, p53), viral oncoproteins (ras, hepatitis B virus, latent membrane protein-1 (LMP-1), human papillomavirus E6/ E7), and anti-apoptosis proteins (Bcl-2). 13,14,16 -25 In this context, diverse antineoplastic effects mediated by intrabodies have been reported, including tumor cell-specific cytotoxicity, chemosensitization, and radiosensitization. 24 -27 These utilities have predicated the evaluation of intrabodies in the context of a human clinical gene therapy trial whereby an anti-erbB-2 intrabody has been studied in a phase I protocol for erbB-2 overexpressing carcinoma of the ovary. 28 The functional basis of intrabody utility is closely linked to the ability of the scFv to interact with its target and prevent its maturation, thus limiting its contribution to the neoplastic phenotype. Thus, for optimal function an intrabody must be expressed in target cells at high levels, achieve appropriate subcellular localization permitting interaction with its target, and maintain high affinity sufficient for effective capture of the corresponding oncoprotein. To this end, we have explored the utility of efficient gene delivery vehicles in the context of intrabody knockout strategies. [27] [28] [29] [30] In addition, our group and others have confirmed the key importance of using heterologous cellular processing signals to achieve effective intrabody colocalization with target oncoproteins. 16 -24,30 -32 In the present study, we sought to determine whether improvement in the affinity of the parent scFv could offer an additional means to improve the efficiency of intrabody-mediated oncoprotein knockout. We have reported previously on the utilities of an anti-erbB-2 intrabody approach in the context of erbB-2 overexpressing tumor target. 16 -19 In these studies, our intrabody was derived from the anti-erbB-2 scFv e23. In this regard, screening of a phage display library and sitedirected mutagenesis has been used to obtain an antierbB-2 scFv such that this new derivative anti-erbB-2 scFv, C6.5, possesses an affinity for its target that is 1000 times greater than that for e23. [33] [34] [35] We thus used this scFv to determine the degree to which affinity differential predicated utility for intrabody knockout approaches. Our results demonstrated that affinity enhancement of the parent scFv does not necessarily predict an improvement in intrabody-mediated antineoplastic effects.
MATERIALS AND METHODS

Cell lines
The human ovarian cancer cell line SKOV3.ip1 was a generous gift of Janet Price (MD Anderson Cancer Center, Houston, Tex); the prostate cell line DU-145, the human cervical cell line HeLa, the human lung cancer cell line A549, and the breast cancer cell line MCF-7 were all obtained from the American Type Culture Collection (Manassas, Va) and maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 (DU-145, SKOV3.ip1), DMEM (HeLa), or RPMI 1640 (A549 and MCF-7) (Mediatech, Herndon, Va) supplemented with L-glutamine (300 g/mL), penicillin (100 international units/ mL), streptomycin (25 g/mL), and 10% fetal calf serum at 37°C in a humidified 5% CO 2 atmosphere.
Plasmid construction and preparation
The anti-erbB-2 scFv C6.5 and anti-erbB-2 scFv e23 were cloned into the plasmid pSTCF.KDEL, which contains an endoplasmic reticulum (ER)-retaining signal, giving rise to the plasmids pSTCF.C6.5 and pSTCF.e23. The plasmid pSTC-F.LMP1 was obtained from a similar plasmid encoding the control anti-LMP-1 scFv. The construction was as follows. The scFv expression plasmid pSTCF.KDEL was derived from pSecTagC (Invitrogen, San Diego, Calif). This vector, derived from the plasmid pcDNA3, encodes an immunoglobulin K (IgK) leader sequence that targets encoded proteins into the secretory pathway, followed by a polylinker, an in-frame myc tag epitope, and a KDEL sequence. Expression is driven by the cytomegalovirus promoter. To allow in-frame cloning of SfiI/ NotI-flanked scFvs from pCANTABS5E (Pharmacia Biotech, Uppsala, Sweden) and other scFv phage display vectors, the pSecTagC vector was digested with SfiI and ApaI. The following complementary oligonucleotides were then annealed and ligated into the digested plasmid vector: 5Ј-CGGCCGTTA-ACGCGGCCGCCGGGCC-3Ј and 5Ј-CGGCGGCCGCGT-TAACGGCCGGCT-3Ј. The resulting construct was verified by sequencing and named pSTCF. To construct pSTCF. KDEL, the pSTCF plasmid was digested with NotI and ApaI. The following complementary oligonucleotides were then annealed into the digested plasmid vector: 5Ј-GGCCGCCGAA-CAAAAACTCATCTCAGAAGAGGATCTGAAGAAAA-GACGAACTCTGAGGGGTTCCGCC-3Ј and 5Ј-CTCACA-GAGTTCGTCTTTTTCTGAATTCAGATCCTCTTCTGA-GCTGAGTTTTTGTTCGGC-3Ј. These oligonucleotides replaced the His tag present in the original pSTCF construct with an internal myc tag and the ER retention sequence SEKDEL. Lastly, we cloned our e23 scFv and C6.5 scFv in this construct by using SfiI and NotI restriction sites. The plasmid for the control gene pSTCF.LMP1 was provided by Dr. Alain Piche (University of Sherbrooke, Quebec, Canada).
Plasmid transfection
All transfections were performed by using the adenovirus/ polylysine system (Ad/pL), as described previously. 36 This vector, consisting of a replication-incompetent adenovirus conjugated to poly-L-lysine, has been shown previously to achieve highly efficient transfection of SKOV3.ip1, DU-145, A549, and HeLa cells. Briefly, 6 g of plasmid DNA was conjugated with an optimized amount of Ad/pL vector and 4 g of free poly-L-lysine, constituting one complex. Complexes were diluted in culture medium containing 2% fetal calf serum and added to cells in 6-well plates at a ratio of 1 complex to 1 million cells. After 1 hour, an equal volume of complete medium was added to the wells. Cells were then harvested and analyzed at various timepoints posttransfection.
For the study of cytotoxicity, a 2.5-L fraction of a single Ad/pL complex was mixed with 100 L of the appropriate 2% medium and incubated with the cells for 1 hour. At that time, 100 L of complete medium was added. Cells were then incubated for 48 -96 hours after transfection and assayed as described below.
Immunoblotting
To assess the expression of protein by Western blot, cells were lysed for 30 minutes on ice with RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 20 mM ethylenediaminetetraacetic acid, and 50 mM tris(hydroxymethyl)aminomethane, pH 7.4) by adding 300 L/well in a 6-well plate. Cells were then scraped, collected in microfuge tubes, and spun at 14,000 rpm for 15 minutes at 4°C. Supernatants were removed, and the protein concentration was assessed using the Bio-Rad protein assay (Bio-Rad, Hercules, Calif) according to the manufacturer's instructions. After mixture with 2ϫ gel-loading buffer, 50 g of total protein was separated on 12% SDS-polyacrylamide gel electrophoresis (PAGE) gel (scFv) followed by transfer to a polyvinylidene difluoride membrane (Bio-Rad). Membranes were probed with the anti-myc tag antibody 9E10 (Invitrogen, Carlsbad, Calif) at a dilution of 1/2500, for scFv detection. Horseradish peroxidase-labeled goat anti-mouse was used at a dilution of 1/5000 as secondary antibody. Western blots were developed using the Renaissance reagent system (DuPont, Boston, Mass).
Immunoprecipitation
To evaluate the interaction of the erbB-2 protein with the anti-erbB-2 scFv, the whole cell lysate from DU-145 cells transfected with the erbB-2 scFv plasmid was prepared as described above. It was then immunoprecipitated with a monoclonal human erbB-2 antiserum (Ab-3; Calbiochem, La Jolla, Calif). To this end, the antibody was mixed with 500 L of immunoprecipitation wash buffer (50 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.4), 150 mM NaCl, 1 mM sodium vanadate, 1% Triton X-100, 10% glycerol), 500 L of Gold buffer (2 mM tris(hydroxymethyl)aminomethane, 150 mM NaCl, gelatin, 0.1% bovine serum albumin, 0.5% Tween 20, 0.02% sodium azide), and 30 L of protein A/G plus agarose beads (Santa Cruz Biotechnology, Santa Cruz, Calif) and rotated overnight at 4°C. The beads were then washed by brief centrifugation, followed by resuspension in 1 mL of immunoprecipitation wash buffer. This step was repeated five times. The beads were then resuspend with 500 L of the cell lysate and rotated at 4°C for 2 hours. After washing as described above, beads were resuspended in 100 L of 1ϫ SDS-PAGE sample buffer and placed on a 100°C heat block for 10 minutes. The samples were then evaluated by SDS-PAGE on a 12% gel, immunoblotted onto polyvinylidene difluoride membranes (Bio-Rad), and probed with anti-myc tag sera, as described above.
Cellular cytotoxicity
The effect of expression of the anti-erbB-2 scFv on cell growth and viability was determined using the Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation/Cytotoxic assay (Promega, Madison, Wis). This MTS-based colorimetric assay measures the ability of viable cells to convert a tetrazolium salt to the formazan compound. To accomplish this analysis, cells were seeded into 96-well cell culture plates at a density of 5000 cells/well. Transfer of the scFv-encoding plasmids pSTCF.e23, pSTCF.C6.5, and pSTCF.LMP1 was performed using the Ad/pL system, as described above. A 2.5-L fraction of a single Ad/pL complex was mixed with 100 L of appropriate 2% medium and incubated with the cells for 1 hour, at which point 100 L of complete medium was added. The plate was subsequently incubated for up to 96 hours. The Cell Titer 96 kit was then used according to the manufacturer's instructions. The percentage of viability was calculated using the following formula: ([infected cells Ϫ blank]/ [uninfected cells Ϫ blank]) ϫ 100.
RESULTS
Plasmids were derived for intracellular eukaryotic expression of the anti-erbB-2 scFvs e23 and C6.5. Plasmid elements include an IgK leader sequence, a minor terminal leader sequence, a carboxy-terminal myc epitope tag, and a KEDEL signal for the achievement of retention of the expressed protein in the ER (Fig 1) . Constructions were confirmed by digestion with restriction endonucleases and restriction analyses (data not shown). High-efficiency transfection of this plasmid construct was achieved via Ad/pL conjugate using described techniques. 36 Initial analyses sought to confirm that the e23 or C6.5 intrabody construct could achieve comparable levels of intracellular expression. Such an outcome would thus allow attribution of any differential biologic effects to the affinity difference of the scFvs. The initial study used the erbB-2-negative human cervical cell line HeLa. Transfection of the HeLa cells with Ad/pL conjugate containing the e23 plasmid pSTCF.e23 yielded a 35-kDa band when cell lysates were analyzed with an anti-myc antibody by immunoblot (Fig 2A) . The appropriate size of the anti-erbB-2 intrabody was confirmed by comparison with the control plasmid pSTCF.LMP1. This construct encodes an scFv to a target irrelevant to the current analysis, the LMP-1 protein of Epstein-Barr virus. Of note, the plasmid pSTCF.C6.5 resulted in expression of an appropriate size protein in amounts Figure 1 . Coding region of plasmids pSTCF.e23 and pSTCF.C6.5. Open reading frame-derived scFvs (e23 and C6.5) were constructed into the parent plasmid pSecTagC. The coding region of the parent plasmid contains an ATG start site, an IgK leader sequence, the scFv cDNA, and a myc epitope tag and KDEL signal for retention in the ER, followed by a TAA stop signal. equal to that achieved by transfection of pSTCF.e23. Thus, the plasmid-driven expression of scFv e23 and scFv C6.5 are associated with comparable levels of anti-erbB-2 intrabody.
We subsequently sought to validate that the intracellular expression of the anti-erbB-2 scFv was capable of achieving interaction with that target. For this analysis, the target erbB-2-negative HeLa cell line and erbB-2-positive-DU-145 cell line were transfected with the plasmid constructs as described previously. Cell lysate from transfected cells was then immunoprecipitated with anti-erbB-2 antibody and subjected to denaturing gel resolution followed by immunoblot with anti-myc antibody. In this study, both of the anti-erbB-2 scFvs were detected from transfection of the erbB-2-positive cell line DU-145 (Fig 2B) . This finding confirmed that both anti-erbB-2 antibodies possessed the capacity to recognize their cognate target in the context of intracellular expression. As a control, similar analysis of the erbB-2-negative HeLa cell line did not exhibit any retained intrabody, confirming the anti-erbB-2 specificity of the intracellularly expressed scFv. To this point, we had thus established that the anti-erbB-2 scFvs were both capable of recognizing their cognate target in an intracellular context and were both associated with comparable levels of intracellular expression of intrabodies.
On this basis, it was thus relevant to directly compare the efficacy of the intrabodies in achieving antineoplastic effects. In this regard, our previous studies have demonstrated that intracellular expression of anti-erbB-2 scFvs can induce a direct cytotoxicity in erbB-2-expressing tumor cells. [17] [18] [19] Thus, we sought to directly compare the e23 and C6.5 intrabodies for this capacity in the context of the erbB-2-positive prostate carcinoma cell line DU-145. Cells were transfected with the conjugate Ad/pL containing either pSTCF.e23 or pSTCF.C6.5 and analysis was carried out at different times posttransfection for viable cell number. In this study, it could be seen that the e23 intrabody elicited significant cytotoxicity compared with Ad/pL conjugates containing the control plasmid pSTCF.LMP1 (Fig 3) . Of note, the C6.5 intrabody induced a level of cytotoxicity comparable with the e23 antibody. The level of plasmid delivered in this study was not sufficient to induce quantitative tumor cell cytotoxicity. On this basis, any differential cytotoxicity of the test intrabodies would have been apparent in this study. Thus, despite the differential target affinity of the e23 and C6.5 scFvs, their derivative intrabodies were of comparable efficiency in inducing tumor cell cytotoxicity.
We compared the intrabodies in two additional ways. First, we have found previously that the level of erbB-2 in target cells is an important predictor of anti-erbB-2 intrabody-mediated cytotoxicity. 17 Therefore, we carried out paired transduction of the e23-and C6.5-encoding plasmids in the context of target tumor cell lines expressing variable levels of erbB-2. As determined previously, Ad/pL transfection of the plasmid was followed by an analysis of cell survival. In this study, there was no significant difference in intrabody-mediated cytotoxicity for the e23 and C6.5 intrabodies (Fig 4) . Thus, even in the context of variable levels of the erbB-2 target, the differential affinity of the e23 and C6.5 scFvs did not predict a differentiated antitumoral efficacy of the derivative intrabody.
In addition, we explored the potency of the intrabodies in the context of a limiting dilution analysis. In this regard, our previous studies have demonstrated a threshold effect for intrabody-mediated cytotoxicity. 37 In these studies, it was shown that a requisite level of intrabody plus target was required to elicit tumor cell cytotoxicity. Therefor, we hypothesized that the higher affinity of the C6.5 scFv for its target might be manifested if limiting levels of the intrabody were expressed. Target DU-145 cells were thus transfected with various levels of the plasmids pSTCF.e23 and pSTCF.C6.5. Analyses for cytotoxicity were endeavored as before. Although a threshold effect could be noticed for cytotoxicity, the threshold levels did not differ for the test intrabodies (Fig 5) . It was thus apparent that the differential efficacy of the intrabodies, manifested as doserelated potency, was not attributable to the differential binding affinities of the parent scFvs.
DISCUSSION
Oncogene knockout represents an attractive cancer gene therapy approach whereby a highly targeted intervention may be achieved. [2] [3] [4] [5] [6] Based on this concept, a number of methods have been endeavored to achieve selective gene product abrogation as a means to revert the transformed phenotype. These interventions have included antisense molecules and ribozymes designed to interrupt oncogene expression at the transcriptional level, as well as dominant-negative molecules and intrabodies to achieve direct oncoprotein knockout. 9 -16 The capacity of these agents to achieve a highly selective antitumoral effect might be clinically advantageous. This hypothesis is currently being evaluated in human clinical trials. 28 In this context, intrabodies offer a number of practical advantages, which have warranted their further study. Chief among these advantages is the facile means whereby anti-oncoprotein scFvs may be derived. Such methods have included genetic techniques of deriving cDNA directly from hybridomas [21] [22] [23] [24] [25] 34 as well as biopanning of phage scFv 33, 35 libraries and others. 38 These methods have allowed direct isolation of scFvs against virtually any subcellular target protein. Thus, unlike antisense molecules and ribozymes, whereby specific recognition and ablation of target oncogenes sequences must be empirically determined, scFvs may be reliably derived from accessible substrate systems for use as intrabodies.
The inhibitory effect of each scFv depends upon achieving sufficiently high levels of expression in the appropriate intracellular localization and upon retaining their binding affinity to the corresponding oncoprotein. In this regard, scFvs may be directed to selected subcellular compartments via heterologous processing signals, and this capacity has allowed knockout of oncoproteins within the nucleus, cytosol, mitochondrial membrane, and ER. [21] [22] [23] [24] 31 Intracellular expression of scFv, however, is a parameter that cannot be predicted a priori. On this basis, limited panels of derived scFvs must be directly screened in the context of eukaryotic cells for determination of the optimal expression profile. Subsequent to the achievement of threshold expression at the appropriate locale, the intrabody is presumed to interact with its target based on affinity dynamics derived from the parental scFv.
In the current study, we sought to determine whether affinity enhancement in the parental scFv would augment the antineoplastic efficacy of the derivative intrabody. In this regard, various techniques have been used to improve the affinity of scFvs for cognate targets. [33] [34] [35] Such efforts have largely been endeavored in the context of the comparison of recombinant immunotoxins, whereby the affinity of the antibody clearly correlated with tumor targeting and with the overall therapeutic efficacy. In our studies, increasing the binding affinity of the scFv did not translate into an improvement in intrabody-mediated tumor cell cytotoxicity induction. A variety of considerations may be invoked to explain this result. First, it is not feasible to actually determine the affinity of the intrabody for its target in the intracellular context; it is plausible that the affinity differential of the e23 and C6.5 scFvs was not maintained at its ER site of intrabody residence. Alternatively, the colocalization of the intrabody and target erbB-2 within the confinement of the ER may allow interactions of a magnitude whereby affinity augmentation is irrelevant. In either event, these studies serve to highlight the degree to which a direct extrapolation of the utilities of scFvs to the intrabody context does not have universal validity.
In our human trial, we have used an anti-erbB-2 scFv for erbB-2 overexpressing carcinoma of the ovary. 28 These studies, as well as preclinical studies in murine model systems, have served to highlight gene delivery into tumor cells as the major practical limitation in realizing the full benefit of intrabody approaches. 39 On this basis, intrabodies may be considered in the context of various other mutation compensation approaches, whereby direct tumor cell transduction is requisite for antitumoral action. As such, these various approaches require quantitative or near-quantitative tumor cell transduction to allow a therapeutic result. The recognition that no vector system can presently achieve this end thus belies the notion that intrabodies, or any mutation compensation approach, are currently rational for clinical cancer gene therapy applications. Nonetheless, strategies to potentially improve biologic action in the context of limited gene delivery, such as we have endeavored herein, remain an area of legitimate pursuit to realize the conceptual benefits potentially offered by oncogene knockout approaches.
